Feb 3 2014
Admedus (ASX: AHZ) today announced that interim study results on its Phase 1 trial of a therapeutic vaccine for Herpes Simplex Virus (HSV-2) have shown that it achieved the primary endpoint of the study by being safe in the study subjects. In addition, the study has also shown that the vaccine was able to generate a T-cell response.
The dosing of study subjects was completed in December 2013 and further analysis of the data in still ongoing. Admedus anticipates providing further study data later in the year.
“This is an encouraging result for the core vaccine technology and provides us with the basis for not only progressing the Herpes therapeutic vaccine program, but also preparing the Human Papillomavirus vaccine for initial clinical studies as a therapeutic against HPV and Cervical Cancer” said Admedus CEO Mr Lee Rodne.
The core technology is based on Professor Ian Frazer and his team’s work over the last 10 years. The technology looks at stimulating the immune response to enable a patient to fight against diseases.
“The results are very encouraging and we believe we should progress these programs forward” said Professor Ian Frazer.
“Once we complete our analysis the team will be looking to take this program into a second clinical study in patients infected with the Herpes virus”.
Currently there is no cure for Herpes and incidence is high. The US CDC estimates that 1 in 6 people in the USA between the age of 14 and 49 have contracted the infection. There is currently no cure for Herpes Simplex 2 infection.
New malaria vaccine strain shows promise in preclinical trials